Burns J W & Co. Inc. NY lowered its holdings in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 29.2% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,067 shares of the medical instruments supplier's stock after selling 2,091 shares during the period. Burns J W & Co. Inc. NY's holdings in Becton, Dickinson and Company were worth $1,161,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Bank of Jackson Hole Trust acquired a new position in Becton, Dickinson and Company in the 4th quarter valued at approximately $25,000. Sierra Ocean LLC bought a new position in shares of Becton, Dickinson and Company in the fourth quarter valued at $29,000. REAP Financial Group LLC raised its holdings in shares of Becton, Dickinson and Company by 75.3% in the fourth quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock valued at $29,000 after purchasing an additional 55 shares during the last quarter. Picton Mahoney Asset Management raised its holdings in shares of Becton, Dickinson and Company by 61.4% in the fourth quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier's stock valued at $32,000 after purchasing an additional 54 shares during the last quarter. Finally, Nexus Investment Management ULC purchased a new stake in Becton, Dickinson and Company during the first quarter worth about $34,000. Institutional investors own 86.97% of the company's stock.
Wall Street Analysts Forecast Growth
Several equities analysts have recently weighed in on the stock. Bank of America downgraded shares of Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $190.00 target price for the company. in a research note on Thursday, May 1st. Piper Sandler downgraded shares of Becton, Dickinson and Company from an "overweight" rating to a "neutral" rating and reduced their target price for the stock from $260.00 to $185.00 in a research note on Friday, May 2nd. Raymond James downgraded shares of Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research note on Friday, May 2nd. Wells Fargo & Company lowered shares of Becton, Dickinson and Company from an "overweight" rating to an "equal weight" rating in a research report on Thursday, May 1st. Finally, The Goldman Sachs Group lowered shares of Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $192.00 price objective for the company. in a research report on Friday, May 2nd. Eight research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $221.44.
Check Out Our Latest Analysis on BDX
Becton, Dickinson and Company Price Performance
Shares of BDX stock traded down $3.33 during trading hours on Monday, reaching $169.26. The stock had a trading volume of 3,262,703 shares, compared to its average volume of 1,933,955. Becton, Dickinson and Company has a 12 month low of $163.33 and a 12 month high of $251.99. The firm has a market capitalization of $48.51 billion, a PE ratio of 28.12, a PEG ratio of 1.63 and a beta of 0.31. The company has a current ratio of 1.13, a quick ratio of 0.63 and a debt-to-equity ratio of 0.69. The stock's fifty day simple moving average is $192.64 and its 200 day simple moving average is $216.56.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.28 by $0.07. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. The business had revenue of $5.27 billion during the quarter, compared to analyst estimates of $5.35 billion. During the same period in the previous year, the business posted $3.17 earnings per share. Becton, Dickinson and Company's revenue for the quarter was up 4.5% on a year-over-year basis. On average, equities research analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current year.
Becton, Dickinson and Company Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Monday, June 30th. Shareholders of record on Monday, June 9th will be given a dividend of $1.04 per share. The ex-dividend date is Monday, June 9th. This represents a $4.16 annualized dividend and a yield of 2.46%. Becton, Dickinson and Company's payout ratio is presently 79.39%.
Insider Buying and Selling at Becton, Dickinson and Company
In other news, EVP Richard Byrd sold 1,940 shares of the business's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $224.91, for a total value of $436,325.40. Following the completion of the sale, the executive vice president now directly owns 7,411 shares in the company, valued at approximately $1,666,808.01. The trade was a 20.75% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Michael David Garrison sold 479 shares of the business's stock in a transaction that occurred on Wednesday, April 9th. The stock was sold at an average price of $197.28, for a total transaction of $94,497.12. Following the completion of the sale, the executive vice president now owns 4,887 shares of the company's stock, valued at approximately $964,107.36. The trade was a 8.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 2,878 shares of company stock worth $636,393 over the last three months. 0.36% of the stock is owned by insiders.
Becton, Dickinson and Company Company Profile
(
Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Recommended Stories
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
